| Revision as of 09:39, 20 July 2006 editBluebot (talk | contribs)349,597 edits formatting← Previous edit | Revision as of 09:11, 14 October 2006 edit undoEveryking (talk | contribs)155,603 editsmNo edit summaryNext edit → | ||
| Line 1: | Line 1: | ||
| Dr. '''Thomas McGlashan''' is a professor of ] at ]. He was born in ]. According to the ], ], ], McGlashan "strived for years to master ], only to reject it outright after demonstrating, in a landmark ] study, that the treatment did not help much at all in people ... with ]." | Dr. '''Thomas McGlashan''' is a professor of ] at ]. He was born in ]. According to the ], ], ], McGlashan "strived for years to master ], only to reject it outright after demonstrating, in a landmark ] study, that the treatment did not help much at all in people ... with ]." | ||
| Disappointed with psychoanalysis, Dr. McGlashan then studied the benefits of antipsychotic medical drugs. In the 1990's he embarked on a study of how useful such drugs can be in preventing ] in adolescents at high risk. In May ], "Dr. McGlashan reported that the drugs were more likely to induce weight gain than to produce a significant, measurable benefit." | |||
Revision as of 09:11, 14 October 2006
Dr. Thomas McGlashan is a professor of psychiatry at Yale University. He was born in 1942. According to the New York Times, May 23, 2006, McGlashan "strived for years to master psychoanalysis, only to reject it outright after demonstrating, in a landmark 1984 study, that the treatment did not help much at all in people ... with schizophrenia."
Disappointed with psychoanalysis, Dr. McGlashan then studied the benefits of antipsychotic medical drugs. In the 1990's he embarked on a study of how useful such drugs can be in preventing psychosis in adolescents at high risk. In May 2006, "Dr. McGlashan reported that the drugs were more likely to induce weight gain than to produce a significant, measurable benefit."
 | This psychology-related article is a stub. You can help Misplaced Pages by expanding it. |